Intravitreal injection is the primary method to treat endophthalmitis, submacular/vitreous hemorrhage, retinal vascular occlusion, advanced AMD, and diabetic retinopathy.8,9 In recent years, the acceptance of intravitreal injections has grown rapidly because of the injection of VEGF inhibitors, which slows down the progress of neovascular retinal diseases, such as exudative AMD and diabetic retinopathy.7,10 In 2012, more than 2.3 million injections were reported, and the number was estimated to reach 6 million in 2016.11 The gene discussed is VEGFA; the disease is age-related macular degeneration.